In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 9.03 below Synlogic Inc average.

Within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Quick Ratio than Synlogic Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 304 to 442.

Explain Quick Ratio?
How much Cash & cash equivalents SYBX�s has?
What are SYBX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SYBX Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	46.54 %	32.85 %	-85.61 %	-87.38 %	-82.36 %
Y / Y Cash & cash equivalent Change	-22.48 %	-18.33 %	-22.23 %	-19.59 %	-14.72 %
Quick Ratio MRQ	9.03	10.35	14.41	16.16	17.08
SYBX's Total Ranking	# 442	# 304	# 137	# 164	# 144
Seq. Current Liabilities Change	7.19 %	33.89 %	5.49 %	-3.21 %	-2.83 %
Seq. Cash & cash equivalent Change	-6.42 %	-3.84 %	-5.92 %	-8.43 %	-1.41 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 117
Healthcare Sector	# 178
Overall Market	# 442

Quick Ratio Statistics
High	Average	Low
1015.34	43.36	2.34
(Jun 30 2017)		(Dec 31 2023)

Financial Statements
Synlogic Inc 's Current Liabilities	$ 1 Millions	Visit SYBX's Balance sheet
Synlogic Inc 's Cash & cash equivalent	$ 13 Millions	Visit SYBX's Balance sheet
Source of SYBX's Sales		Visit SYBX's Sales by Geography

Cumulative Synlogic Inc 's Quick Ratio

SYBX's Quick Ratio for the trailling 12 Months

SYBX Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-71.29 %	-79.71 %	-87.21 %	-77.46 %	-63.71 %
Y / Y Cash & cash equivalent TTM Growth	-20.65 %	-18.67 %	-28.69 %	-42.43 %	-45.63 %
Quick Ratio TTM	11.98	14.14	16.12	6.83	4.33
Total Ranking TTM	# 3606	# 2620	# 2385	# 2802	# 2914
Seq. Current Liabilities TTM Growth	10.68 %	8.41 %	-60.19 %	-39.9 %	-21.75 %
Seq. Cash & cash equivalent TTM Growth	-6.23 %	-4.9 %	-6.1 %	-5.24 %	-3.89 %

Quick ratio ranking by company, industry and sector >> Back to SYBX Financial Strength Comparisons >> Go to Compare SYBX Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2026 to $1.46 millions, cumulative Quick Ratio decreased to 11.98 above the SYBX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 423 other companies have achieved higher Quick Ratio than Synlogic Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2620 to 3606.

Explain Quick Ratio?
How much Cash & cash equivalents SYBX�s has?
What are SYBX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 424
Healthcare Sector	# 863
Within the Market	# 3606

trailing twelve months Quick Ratio Statistics
High	Average	Low
8.46	3.72	1.44
(Dec 31 2016)		(Sep 30 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Prothena Corporation Public Limited Company	24.72	$ 288.193 Millions	$ 11.658 Millions
Zenas Biopharma Inc	24.28	$ 1,597.761 Millions	$ 65.818 Millions
Neuphoria Therapeutics Inc	23.89	$ 19.866 Millions	$ 0.832 Millions
Innoviva Inc	23.77	$ 1,118.871 Millions	$ 47.064 Millions
Pepgen Inc	23.51	$ 211.674 Millions	$ 9.005 Millions
Kailera Therapeutics Inc	23.41	$ 1,958.240 Millions	$ 83.651 Millions
Equillium Inc	23.07	$ 57.164 Millions	$ 2.478 Millions
Relmada Therapeutics Inc	21.72	$ 217.731 Millions	$ 10.023 Millions
Keros Therapeutics Inc	21.20	$ 257.606 Millions	$ 12.153 Millions
Protagonist Therapeutics inc	21.05	$ 782.576 Millions	$ 37.181 Millions
Stablecoin Development Corporation	20.76	$ 7.122 Millions	$ 0.343 Millions
Rhythm Pharmaceuticals Inc	20.65	$ 596.183 Millions	$ 28.868 Millions
Structure Therapeutics Inc	20.31	$ 1,342.700 Millions	$ 66.113 Millions
Scynexis Inc	19.69	$ 114.696 Millions	$ 5.825 Millions
Q32 Bio Inc	19.68	$ 106.270 Millions	$ 5.401 Millions
Damora Therapeutics Inc	19.62	$ 540.515 Millions	$ 27.550 Millions
Kairos Pharma Ltd	19.12	$ 5.067 Millions	$ 0.265 Millions
Minerva Neurosciences Inc	19.02	$ 75.267 Millions	$ 3.958 Millions
Abcellera Biologics Inc	18.05	$ 960.143 Millions	$ 53.189 Millions
Sellas Life Sciences Group Inc	17.29	$ 138.443 Millions	$ 8.006 Millions
Whitehawk Therapeutics Inc	17.17	$ 190.000 Millions	$ 11.069 Millions
Forte Biosciences Inc	17.12	$ 347.331 Millions	$ 20.289 Millions
Ovid Therapeutics Inc	17.01	$ 169.769 Millions	$ 9.980 Millions
Bioage Labs Inc	16.59	$ 318.745 Millions	$ 19.217 Millions
Olema Pharmaceuticals Inc	16.48	$ 873.571 Millions	$ 53.014 Millions
Erasca Inc	16.41	$ 610.496 Millions	$ 37.200 Millions
Janux Therapeutics Inc	16.14	$ 970.913 Millions	$ 60.152 Millions
Edgewise Therapeutics inc	15.86	$ 460.709 Millions	$ 29.042 Millions
Corvus Pharmaceuticals Inc	15.74	$ 215.200 Millions	$ 13.672 Millions
Telomir Pharmaceuticals Inc	15.55	$ 5.170 Millions	$ 0.332 Millions

Date modified: 2026-09-03T02:40:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.